5. REFERENCES
Zwaan CM, Reinhardt D, Hitzler et al., Acute leukemias in children with
Down Syndrome. Hematol Oncol Clin North Am. 2010; 24(1): 19-34.
Hashle H, Abrahamsson J, Arola M, et al.; Myeloid leukemia in Children 4
years or older with Down syndrome often lacks GATA1 mutation and
cytogenetics and risk of relapse are more akin to sporadic AML.
Leukemia. 2008; 22(7): 1428-30.
Creutzig U, Reinhardt D, Diekamp S, et al., AML patients with Down
syndrome have a high cure rate with AML-BFM therapy with reduced dose
intensity. Leukemia. 2005; 19(8): 1355-60.
Taga T, Tomizawa D, Takahashi H and Adachi S. Acute Myeloid Leukemia in
Children: Current status and future Directions. Pediatrics
International. 2016; 58, 71-80.
Lam GKS, Leung AWK, Ha SY et al., Acute Leukemia in Down Syndrome
Children in Hong Kong A Retrospective Review. J Pediatr Hematol Oncol
2016;38:102-6.
Lins MM, Mello MJG, Riberior RC, Camargo B, Fatima A, and Thuler L.
Survival and Risk factors for Mortality in Pediatric Patients with Acute
Myeloid Leukemia in a Single Reference Center in Low-Middle-Income
Country. Annals of Hematology. 2019; 98(6):1403-11.
Ravindranath Y, Abella E, Krischer JP, et al., Acute myeloid leukemia
(AML) in Down’s syndrome is highly responsive to chemotherapy:
experience on Pediatric Oncology Group AML Study 8489. Blood.
1992;80(9): 2210-14.
Stewart CF. Treating children with acute lymphoblastic leukemia and Down
syndrome: pharmacokinetics provides insight into vincristine therapy.
Pediatr Blood Cancer. 2009; 52(1):1-2.
Yamashita Y, Tohda S, nagata K,
Suzuki T, Imai Y, and Nara N. The In Vitro Effect of Vincristine on the
Blast Cell Renewal in Acute Myeloblastic Leukemia. Jpn J Med. 1991;
30(5): 412-9.
Zwaan CM, Kaspers GJL, Veerman AJP et al., Different drug sensitivity
profile of acute myeloid and lymphoblastic leukemia and normal
peripheral blood mononuclear cells in children with and without Down
syndrome. Blood. 2002;99:245-251.
Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, Heerema
NA, Bhatia S. Clinical characteristics and outcome of children with Down
syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group
study. Blood. 2005; 106(13): 4043-9.
Matloub et al. Excellent long-term survival of children with Down
syndrome and standard-risk ALL: a report from the Children’s Oncology
Group. Blood Adv. 2019; 3(11): 1647-5.
Al-Ahmari A, Shah N, Sung L, et al., Long-term results of an Ultra
Low-Dose Cytarabine based regimen for the treatment of Acute
megakaryoblasti Leukaemia in Children with Down Syndrome. Br J Haematol.
2006;133(6):646-648.
Taub JW, Berman JN, Hitzler JK, Sorrell AD et al., Improved Outcomes for
Myeloid leukemia of Down syndrome: a report from the Children’s Oncology
Group AAML0431 trial. Blood. 2017; 129: 3304-3313.
Uffman M, Rasche M, Zimmerman M et al., Therapy reduction in patients
with Down syndrome and myeloid leukemia: the international ML-DS 2006
trial. Blood. 2017;129(25):3314-3321.